Skip to main content
Premium Trial:

Request an Annual Quote

Cellink to Acquire Single-Cell Dispensing Firm Cytena for €30.3M

NEW YORK — Bioprinting technology developer Cellink said today that it has signed an agreement to acquire Cytena of Germany for €30.3 million ($33.8 million) in cash and stock.

Cytena, which was spun out of the University of Freiburg's Institute for Microsystems Technology in 2014, has developed a printer technology that allows users to isolate and dispense single cells for genomics research and clonal cell line development for biopharmaceutical production. Earlier this year, the company closed a €3 million Series A financing round.

According to Boston-based Cellink, the acquisition will complement its portfolio of bioink, bioprinters, rapid dispensers, and live cell imaging systems for creating and tracking human tissues and 3D cell culture models.

Under the terms of the deal, Cellink will acquire Cytena for €11.4 million in cash and 674,678 newly issued shares valued at €18.9 million. The transaction will give Cytena's shareholders a roughly 5 percent voting stake in Cellink and about 7 percent of the firm's share capital. Following the acquisition, Cytena will retain its current management.

Additional terms were not disclosed.

"We are furthering Cellink's global commercial strategy by focusing on the pharmaceutical industry and providing the most innovative solutions to researchers around the world," Cellink CEO Erik Gatenholm said in a statement. "With Cytena's revolutionary technology platforms, we will streamline workflows for our present and future customers, and enhance our presence in the pharmaceutical industry."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.